Glaxo to Seek Approval for Malaria Vaccine

Trial Indicates Partial Protection Against the Disease

Drug maker GlaxoSmithKline PLC said it intends to submit an experimental malaria vaccine for regulatory approval next year, after new data from a long-running study continued to show that the vaccine provides partial protection against the disease.

Although the vaccine doesn't appear to work as well as originally hoped, both Glaxo and the charitable group helping fund the vaccine trial, the Path Malaria Vaccine Initiative, said it...